Lilly’s Lower-Cost Zepbound Options Could Ease Patient Transition From Compounded GLP-1s

Lilly is broadening the range of single-use vial dosage forms of its obesity drug and lowering prices of existing doses for self-paying customers, but maintains it can handle increased demand as compounding ends.